
    
      This is a Phase I, open study, non-controlled, to evaluate the safety, tolerability and
      imunogenicity of double viral vaccine anti-measles and rubella (MR), which is developed and
      produced at Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos/Fiocruz, in Brazil, for
      use in human beings. 30 eligible volunteers, between 18-49 years old, will be vaccinated and
      monitored for local and systemic adverse events and titration of antibodies. The study will
      last 20 months in total.
    
  